- Home
- SOAR vs SNGX Comparison
SOAR vs SNGX Comparison
Compare SOAR & SNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SOAR
- SNGX
- Stock Information
- Founded
- SOAR 2021
- SNGX 1987
- Country
- SOAR United States
- SNGX United States
- Employees
- SOAR N/A
- SNGX N/A
- Industry
- SOAR Blank Checks
- SNGX Biotechnology: Pharmaceutical Preparations
- Sector
- SOAR Finance
- SNGX Health Care
- Exchange
- SOAR Nasdaq
- SNGX Nasdaq
- Market Cap
- SOAR 9.4M
- SNGX 10.1M
- IPO Year
- SOAR N/A
- SNGX 1987
- Fundamental
- Price
- SOAR $1.65
- SNGX $2.92
- Analyst Decision
- SOAR
- SNGX Strong Buy
- Analyst Count
- SOAR 0
- SNGX 1
- Target Price
- SOAR N/A
- SNGX $6.00
- AVG Volume (30 Days)
- SOAR 498.3K
- SNGX 10.0M
- Earning Date
- SOAR 08-14-2025
- SNGX 11-07-2025
- Dividend Yield
- SOAR N/A
- SNGX N/A
- EPS Growth
- SOAR N/A
- SNGX N/A
- EPS
- SOAR N/A
- SNGX N/A
- Revenue
- SOAR $96,397,000.00
- SNGX N/A
- Revenue This Year
- SOAR N/A
- SNGX N/A
- Revenue Next Year
- SOAR N/A
- SNGX N/A
- P/E Ratio
- SOAR N/A
- SNGX N/A
- Revenue Growth
- SOAR 309.80
- SNGX N/A
- 52 Week Low
- SOAR $1.14
- SNGX $1.09
- 52 Week High
- SOAR $19.06
- SNGX $6.23
- Technical
- Relative Strength Index (RSI)
- SOAR 53.65
- SNGX 51.64
- Support Level
- SOAR $1.52
- SNGX $2.58
- Resistance Level
- SOAR $1.66
- SNGX $3.11
- Average True Range (ATR)
- SOAR 0.13
- SNGX 0.22
- MACD
- SOAR -0.00
- SNGX -0.09
- Stochastic Oscillator
- SOAR 46.48
- SNGX 43.59
About SOAR Volato Group Inc.
Volato Group Inc operates an aircraft ownership program, provides ad-hoc charter flights, sells deposit products, and manages aircraft for owners in the private aviation industry. It offers fractional ownership, aircraft management, jet cards, deposit, and charter programs. The company's fractional programs provides flexible hours and a revenue share for owners in a fleet of HondaJets, optimized for missions of up to four passengers.
About SNGX Soligenix Inc.
Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely Specialized BioTherapeutics and Public Health Solutions. It generates maximum revenue from Public Health Solutions with active development programs for RiVax, its ricin toxin vaccine candidate, SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease, and its research programs to identify and develop novel vaccine candidates targeting viral infection including Ebola, Marburg and SARS-CoV-2 (the cause of COVID-19).